Nalidixic Acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318300

CAS#: 389-08-2

Description: Nalidixic Acid is the first of the synthetic quinolone antibiotics. Nalidixic acid is effective primarily against gram-negative bacteria, with minor anti-gram-positive activity. In lower concentrations, it acts in a bacteriostatic manner; that is, it inhibits growth and reproduction. In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.

Price and Availability


USD 150

USD 450

Nalidixic Acid, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318300
Name: Nalidixic Acid
CAS#: 389-08-2
Chemical Formula: C12H12N2O3
Exact Mass: 232.0848
Molecular Weight: 232.2353
Elemental Analysis: C, 62.06; H, 5.21; N, 12.06; O, 20.67

Synonym: Nalidixic Acid, Nevigramon, Neggram, Wintomylon, WIN 18,320

IUPAC/Chemical Name: 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid


InChi Code: InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)

SMILES Code: O=C(C1=CN(CC)C2=C(C=CC(C)=N2)C1=O)O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z, Qian H, Wei Y, Zhao L, Liu G, Tong M. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. Int J Antimicrob Agents. 2012 Jul;40(1):9-17. doi: 10.1016/j.ijantimicag.2012.02.005. Epub 2012 Apr 5. Review. PubMed PMID: 22483324.

2: Shakespeare WA, Davie D, Tonnerre C, Rubin MA, Strong M, Petti CA. Nalidixic acid-resistant Salmonella enterica serotype Typhi presenting as a primary psoas abscess: case report and review of the literature. J Clin Microbiol. 2005 Feb;43(2):996-8. Review. PubMed PMID: 15695728; PubMed Central PMCID: PMC548044.

3: Singh H, Sachdev HP. Nalidixic acid. Indian Pediatr. 1988 Mar;25(3):279-81. Review. PubMed PMID: 3069738.

4: Albrecht R. Development of antibacterial agents of the nalidixic acid type. Prog Drug Res. 1977;21:9-104. Review. PubMed PMID: 339272.

5: Zinsser HH. Nalidixic acid in acute and chronic urinary tract infections. Med Clin North Am. 1970 Sep;54(5):1347-50. Review. PubMed PMID: 4248514.

6: Pagnini G. [Nalidixic acid]. Antibiotica. 1967 Jun;5(2):134-59. Review. Multiple languages. PubMed PMID: 4389549.

7: Parry CM. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg. 2004 Jul;98(7):413-22. Review. PubMed PMID: 15138078.

8: Petersen U. [The evolution of quinolone: from nalidixic acid to the quinolones of the third generation]. Pharm Unserer Zeit. 2001;30(5):376-81. Review. German. PubMed PMID: 11575173.

9: Gleckman R, Alvarez S, Joubert DW, Matthews SJ. Drug therapy reviews: nalidixic acid. Am J Hosp Pharm. 1979 Aug;36(8):1071-6. Review. PubMed PMID: 384787.

10: Bauernfeind A. Mode of action of nalidixic acid. Antibiot Chemother (1971). 1971;17:122-36. Review. PubMed PMID: 4950999.

11: Finegold SM, Ziment I. Sulfonamides, nitrofurans and nalidixic acid. Pediatr Clin North Am. 1968 Feb;15(1):95-105. Review. PubMed PMID: 4866909.